DOCSLIB.ORG

Neurokinin-1 Antagonist Orvepitant for EGFRI- Induced

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurokinin-1 Antagonist Orvepitant for EGFRI- Induced Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-030114 on 6 February 2020. Downloaded from Neurokinin-1 antagonist orvepitant for EGFRI- induced pruritus in patients with cancer: a randomised, placebo- controlled phase II trial Bruno Vincenzi ,1 Mike Trower ,2 Ajay Duggal ,3 Pamela Guglielmini ,4 Peter Harris ,2 David Jackson ,5 Mario E Lacouture ,6 Emiliangelo Ratti ,2 Giuseppe Tonini ,1 Andrew Wood ,7 Sonja Ständer 8 To cite: Vincenzi B, Trower M, ABSTRACT Strengths and limitations of this study Duggal A, et al. Neurokinin-1 Objective To evaluate the efficacy of orvepitant (10 or antagonist orvepitant for 30 mg given once daily, orally for 4 weeks), a neurokinin-1 EGFRI- induced pruritus ► The RELIEVE 1 study was the first randomised, in patients with cancer: a receptor antagonist, compared with placebo in reducing double- blind, placebo- controlled study of a neuroki- randomised, placebo- controlled the intensity of epidermal growth factor receptor inhibitor nin-1 antagonist for epidermal growth factor recep- phase II trial. BMJ Open (EGFRI)- induced intense pruritus. tor inhibitor- induced pruritus. 2020;10:e030114. doi:10.1136/ Design Randomised, double- blind, placebo- controlled ► Patients reported scores for the primary endpoint of bmjopen-2019-030114 clinical trial. reduction of itch intensity on a daily basis using an ► Prepublication history for Setting 15 hospitals in Italy and five hospitals in the UK. interactive voice response system. this paper is available online. Participants 44 patients aged ≥18 years receiving an ► Effects on sleep and quality of life were also To view these files, please visit EGFRI for a histologically confirmed malignant solid tumour measured. the journal online (http:// dx. doi. and experiencing moderate or intense pruritus after EGFRI ► Itch is a subjective symptom and thus susceptible to org/ 10. 1136/ bmjopen- 2019- treatment. a placebo effect. 030114). Intervention 30 or 10 mg orvepitant or placebo tablets ► The enrolment target was not reached because of recruitment problems in the target population. BV and MT contributed equally. once daily for 4 weeks (randomised 1:1:1). Primary and secondary outcome measures The Received 01 March 2019 primary endpoint was change from baseline in mean http://bmjopen.bmj.com/ Revised 11 December 2019 INTRODUCTION Accepted 13 January 2020 patient- recorded numerical rating scale (NRS) score (over the last three recordings) at week 4. Secondary While targeted biological therapies have outcome measures were NRS score, verbal rating increased patient survival for several tumour scale score, Skindex-16 and Leeds Sleep Evaluation types, they are linked with a variety of adverse Questionnaire at each study visit (baseline, weeks 1, events (AE), particularly dermatological 4, 8); rescue medication use; EGFRI dose reduction; AEs, including acneiform rash, hair changes, and study withdrawal because of intense uncontrolled mucositis, xerosis/fissures, paronychia and pruritus. pruritus. Epidermal growth factor receptor on September 30, 2021 by guest. Protected copyright. Results The trial was terminated early because of inhibitors (EGFRI) specifically are associ- recruitment challenges; only 44 of the planned 90 patients ated with these dermatological AEs that were randomised. All patients were analysed for efficacy can require dose modification or treatment and safety. Mean NRS score change from baseline to interruptions and thus interfere with these week 4 was −2.78 (SD: 2.64) points in the 30 mg group, potentially life- prolonging therapies.1–5 Rash, −3.04 (SD: 3.06) points in the 10 mg group and −3.21 (SD: xerosis and pruritus have the greatest impact © Author(s) (or their 1.77) points in the placebo group; the difference between on patient quality of life.5–7 Pruritus inci- employer(s)) 2020. Re- use orvepitant and placebo was not statistically significant. dence reported in clinical trials of anti- EGFR permitted under CC BY-NC. No No safety signal was detected. Adverse events related to monoclonal antibodies (mAb) and small- commercial re- use. See rights orvepitant (asthenia, dizziness, dry mouth, hyperhidrosis) molecule EGFRIs ranges from 8% to 69% and permissions. Published by were all of mild or moderate severity. BMJ. depending on the agent involved.8 9 EGFRI- Conclusions Orvepitant was safe and well tolerated. For numbered affiliations see induced pruritus may be under- reported or No difference in NRS score between the orvepitant and end of article. incompletely reported in clinical studies.10 placebo groups was observed at the week 4 primary In a survey of patients with cancer and survi- Correspondence to endpoint. A number of explanations for this outcome are vors, pruritus is common and debilitating.11 12 Dr Mike Trower; possible. Lacouture et al reported that pruritus occurs mike. trower@ nerretherapeutics. Trial registration number EudraCT2013-002763-25. com in approximately half of all patients treated Vincenzi B, et al. BMJ Open 2020;10:e030114. doi:10.1136/bmjopen-2019-030114 1 Open access BMJ Open: first published as 10.1136/bmjopen-2019-030114 on 6 February 2020. Downloaded from with EGFRIs.4 Finally, in a review of interviews conducted NK1 antagonist that blocks SP signalling.51–53 These with 100 patients taking mainly EGFR mAbs, 72% of compounds are active in the well-characterised NK1 patients reported experiencing pruritus.13 A safe and receptor pharmacodynamic gerbil foot- tapping model, effective cancer- supportive care therapy to ameliorate in preclinical models of anxiety,51–54 and, as reported the itching burden these patients experience is urgently above, in the gerbil scratching behaviour model.28 29 In needed. humans both compounds have pharmacokinetic prop- Neurokinin-1 (NK1) receptors are 7-transmembrane erties consistent with once-daily oral dosing sufficient receptors with a preferred peptide agonist ligand of to achieve therapeutic plasma exposures that have high substance P (SP).14 SP produced by peripheral skin sensory levels of central NK1 receptor occupancy.55 56 Thus, orve- nerve fibres is thought to promote itching via activation pitant would be expected to achieve antipruritic efficacy of NK1 receptors on keratinocytes and mast cells causing similar to that of aprepitant in patients suffering from local inflammatory and vasodilatory effects.15 Interestingly, intense itch as a result of EGFRI treatment. The RELIEVE Gerber et al reported that mast cells significantly accumu- 1 study evaluating the efficacy and safety of orvepitant is late in the lesional skin of patients treated with EGFRIs and the first randomised, double- blind, placebo- controlled suggested that the antipruritic activity of the NK1 receptor study of an NK1 antagonist for EGFRI- induced pruritus. antagonist aprepitant in this population is achieved by blocking the activation of mast cell NK1 receptors by SP, METHODS thereby preventing the release of mast cell histamine Patient and public involvement and other proinflammatory/pruritogenic mediators.16–18 The indication, research questions and study endpoint Recently, another receptor, the Mas- related G- protein outcome measures were selected based on the authors’ coupled receptor member X2, has been shown to be acti- expert understanding in the care of affected patients, vated in humans by SP, and this interaction may contribute their needs and therapy preferences, without direct additionally to the proinflammatory effects mediated by communication of the study design to patients. Expe- mast cell degranulation.19 SP and the NK1 receptor are rience from guideline work, which involved patients’ also widely expressed centrally and have a role in transmis- preferences, was also carried over into the study design. sion of the peripheral itch signal via the spinal superficial Patients were not involved in the recruitment nor conduct dorsal horn to higher brain centres for processing.20 In of the study, nor the interpretation of results. No commit- rodents scratching behaviour can be blocked by neuro- ment was made to disseminate the results to study partic- toxic destruction of spinal NK1 receptor-expressing ipants. Patients assessed the burden of the intervention neurons,21 22 and Tac1 (the gene encoding SP)-expressing themselves. Patients were not invited to contribute to the spinal neurons have also been linked to the promotion writing nor editing of this document for either readability of scratching behaviour.23 Intradermal injection of SP or accuracy. in humans causes pruritus, erythema and oedema.24–26 http://bmjopen.bmj.com/ Study design and enrolment Scratching behaviour induced by intradermal injection The primary objective of this exploratory phase II, multi- of either SP or an NK1 agonist or topical administration centre, randomised, double- blind, placebo- controlled of a hapten in animals can all be profoundly reduced by clinical trial was to evaluate the efficacy of orvepitant NK1 antagonist treatment, including both orvepitant and compared with placebo in reducing the intensity of aprepitant.27–30 These data suggest that the NK1 receptor intense EGFRI- induced pruritus. Pruritus intensity was system is involved in itch signalling and therefore blockade measured primarily by change from baseline in patient- of these pathways with NK1 receptor antagonists represents recorded numerical rating scale (NRS) score ranging on September 30, 2021 by guest. Protected copyright. a potentially promising therapy for pruritic conditions, from 0 (no itch) to 10
Load more

Recommended publications
  • A Randomized, Double-Blind, Placebo-Controlled Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Mo%on Sifnos: A randomized, double-blind, placebo-controlled study demonstra%ng the effec%veness of tradipitant in the treatment of mo%on sickness Vasilios M. Polymeropoulos*1, Mark É. Czeisler1#a, Mary M. Gibson1¶, Aus%n A. Anderson1¶, Jane Miglo1#b, Jingyuan Wang1, Changfu Xiao1, Christos M. Polymeropoulos1, Gunther Birznieks1, Mihael H. Polymeropoulos1 1 Vanda Pharmaceu%cals, Washington, District of Columbia, United States of America #a The Ins%tute for Breathing and Sleeping, Aus%n Health, Heidelberg, Victoria, Australia #b College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States of America *Corresponding author Email: [email protected] (VMP) ¶These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 Abstract Background Novel therapies are needed for the treatment of mo%on sickness given the inadequate relief, and bothersome and dangerous adverse effects of currently approved therapies.
    [Show full text]
  • Compositions for Treating Centrally Mediated
    (19) TZZ Z_T (11) EP 2 722 045 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61K 31/473 (2006.01) 06.07.2016 Bulletin 2016/27 A61K 31/496 (2006.01) A61K 31/573 (2006.01) A61K 45/06 (2006.01) A61K 9/00 (2006.01) (2006.01) (2006.01) (21) Application number: 14151683.1 A61K 9/20 A61K 9/48 A61P 1/08 (2006.01) (22) Date of filing: 18.11.2010 (54) Compositions for treating centrally mediated nausea and vomiting Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen Compositions pour traiter les nausées et vomissements à médiation centrale (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A1-2008/049552 WO-A2-2007/096763 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • REDDY G KESAVA ET AL: "Novel neurokinin-1 antagonists as antiemetics for the treatment of (30) Priority: 18.11.2009 US 262470 P chemotherapy-induced emesis.", SUPPORTIVE 14.09.2010 US 382709 P CANCER THERAPY 1 APR 2006 LNKD- PUBMED:18632487, vol. 3, no. 3, 1 April 2006 (43) Date of publication of application: (2006-04-01), pages140-142, XP002626039, ISSN: 23.04.2014 Bulletin 2014/17 1543-2912 • DIEMUNSCH P ET AL: "Neurokinin-1 receptor (62) Document number(s) of the earlier application(s) in antagonists in the prevention of postoperative accordance with Art.
    [Show full text]
  • ( 12 ) United States Patent
    US009974742B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 974 , 742 B2 Ottoboni et al. (45 ) Date of Patent: * May 22, 2018 ( 54 ) EMULSION FORMULATIONS OF AN NK - 1 2013 /0236501 A1 * 9 /2013 Booth . .. .. .. A61K 9 /0019 424 / 400 RECEPTOR ANTAGONIST AND USES 2013 /0317016 AL 11 /2013 Hingorani et al. THEREOF 2016 / 0024092 Al 1 / 2016 Wan et al. 2016 / 0082013 Al 3 / 2016 Ottoboni et al . @(71 ) Applicant : Heron Therapeutics , Inc. , Redwood 2016 /0206622 A1 3 / 2016 Ottoboni et al . City , CA (US ) 2017 / 0112847 AL 4 /2017 Ottoboni et al. @(72 ) Inventors : Thomas B . Ottoboni, Belmont, CA (US ) ; Han Han , Mountain View , CA FOREIGN PATENT DOCUMENTS (US ) CN 102379 * 3 / 2012 CN 102379845 A 3 / 2012 @(73 ) Assignee : Heron Therapeutics, Inc. , San Diego , WO WO 2005 /016308 AL 2 / 2005 WO WO 2009 / 124756 AL 10 / 2009 CA (US ) WO WO 2011 / 158053 AL 12 / 2011 WO WO 2013 / 177501 A2 11 / 2013 @( * ) Notice : Subject to any disclaimer , the term of this WO WO 2014 /0209962 AL 12 /2014 patent is extended or adjusted under 35 WO WO 2014 /005606 AL 3 / 2016 U . S . C . 154 ( b ) by 0 days . days . WO WO 2016 /044784 Al 3 / 2016 This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS (21 ) Appl. No. : 15 /012 , 532 Cassileth et al. in Arch . Intern Med . 1983 ; 143 ( 7 ) : 1347 - 1349 ( Abstract ) . * Dexamethasone Hydrogen Phosphate at web .archive . org/ web / ( 22 ) Filed : Feb . 1 , 2016 20141224130045 /http :/ /www . drugs . com / pro / dexamethasone -so dium -phosphate .html ( retrieved on the internet Mar.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0038462 A1 ZHANG Et Al
    US 20160038462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0038462 A1 ZHANG et al. (43) Pub. Date: Feb. 11, 2016 (54) USE OF NK-1 RECEPTOR ANTAGONISTS IN (60) Provisional application No. 61/838,784, filed on Jun. PRURTUS 24, 2013. (71) Applicant: TIGERCAT PHARMA, INC., South Publication Classification San Francisco, CA (US) (51) Int. Cl. (72) Inventors: Xiaoming ZHANG, Sunnyvale, CA A613 L/403 (2006.01) (US); Edward F. SCHNIPPER, A6II 45/06 (2006.01) Redwood City, CA (US); Andrew J. A619/00 (2006.01) PERLMAN, Stanford, CA (US); James (52) U.S. Cl. W. LARRICK, Sunnyvale, CA (US) CPC ............. A6 IK3I/403 (2013.01); A61 K9/0053 (2013.01); A61 K9/0014 (2013.01); A61 K (21) Appl. No.: 14/922,684 45/06 (2013.01) (57) ABSTRACT (22)22) Filed: Oct. 26,9 2015 The invention relates to methods for treatingg pruritusp with NK-1 receptor antagonists such as serlopitant. The invention O O further relates to pharmaceutical compositions comprising Related U.S. Application Data NK-1 receptorantagonists such as serlopitant. In addition, the (60) Division of application No. 14/312.942, filed on Jun. invention encompasses treatment of a pruritus-associated 24, 2014, now Pat. No. 9,198.898, which is a continu condition with serlopitant and an additional antipruritic ation-in-part of application No. 13/925,509, filed on agent, and the use of serlopitant as a sleep aid, optionally in Jun. 24, 2013, now Pat. No. 8,906,951. combination with an additional sleep-aiding agent. Patent Application Publication Feb.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD
    Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD This list was graciously provided by JR Becker ([email protected]). Some additions have been made by Shawn Thomas ([email protected]). Please send additions or corrections to [email protected] Information about recent drug approvals can be obtained from the FDA Center for Drug Evaluation and Research. For information about drugs already marketed in the US, see Neurotransmitter.net's Drug Reference for FDA Approved Psychiatric Drugs. A List of Drugs in Development for Neurodegenerative Diseases [PDF] compiled by Myoung-Ok Kwon and colleagues (2004) is available from the journal Neurodegenerative Diseases; 1(2-3):113–152. Please support the NIMH's GenRED (Genetics of Recurrent Early-onset Depression) study, the largest psychiatric genetics study ever attempted. Updated 12/03/07 Treatments for Depression and Anxiety Drug Name Pharmacologic Action Company Indication Developmen Links tal Phase Pristiq (DVS- Metabolite of Effexor Wyeth Depression, Approvable 233 SR, (venlafaxine) anxiety (but further desvenlafaxine needed ) Phase III trials suggest a 2008 approval date) Gepirone ER 5-HT1A partial agonist Fabre- Depression, Not [Fabre- Kramer anxiety Approvable Kramer's Drug Profile] Saredutant (SR NK2 antagonist Sanofi- Depression, Phase III [Effects of SR 48968) Aventis anxiety 48968 on rodents] Valdoxan 5-HT2C antagonist, 5-HT2B Servier, Depression, EU: [Receptor (agomelatine, antagonist, melatonin M1/M2 Novartis anxiety, Resubmissio activity] [Oct AGO 178) receptor agonist sleep n planned in 2005 press disorders ’07. US: release] Phase III Amibegron, SR beta-3-adrenoceptor agonist Sanofi- Depression, A [SR 58611 is 58611 Aventis anxiety supplement a selective al NDA is beta-3- possible in adrenoceptor 2007 agonist] Vilazodone 5-HT1A partial agonist, Clinical Data Depression Phase III [January serotonin reuptake inhibitor Online, Inc.
    [Show full text]
  • Chronic Itch Clinical Cases & Management
    Chronic Itch Clinical Cases & Management Gil Yosipovitch MD FAAD Professor & Director Miami Itch Center DISCLOSURE Disclosures WITH INDUSTRY • Advisory Boards: Trevi, Pfizer, Sanofi, Menlo, Galderma, Sienna • Consultant: Opko LEO, J&J, Menlo, Novartis • PI; Tioga, Roche, Pfizer, Allergen • Funded:, GSK, LEO Foundation, Pfizer, Sun Pharma Outline • Understanding itch of different types • Pathophysiology of itch in PN and its treatment • Atopic itch and its new management • Itch without rash and its management • Neuropathic itch Stander et al. IFSI consensus group. Acta Dermatol 2007 Yosipovitch & Bernhard NEJM 2013 Important Questions to Ask an Itchy Patient • Duration: years/weeks/days • Severity • Localization; generalised/ localized/ • Periodicity; paroxysmal, continuous, occurring in short bouts, nocturnal • Affect on sleep • History of itch in other personal contacts • Factors that exacerbate itch; heat, water, dryness • Factors that alleviate itch (drugs or cooling agents) • Drugs (opiates, aspirin, penicillin, antimalarials) • History of atopy • Travel history PN in African Americans and AD • Population coding • Molecular specificity of receptor activation TSLP IL-33 ST2 TSLPR Il-31 IL-31R Mrgprs H H1, H4 NPPB GRP NPRA Yosipovitch and Bernhard, NEJM. 2013 Apr 25; 368 (17):1625. GRPR Prurigo Nodularis Itch Neurogenic Activation of inflammation, retrograde attraction of signaling inflammatory pathways cells ‘Axiotomy’ of epidermal Scratching peripheral nerve endings Various Forms of Prurigo The first three may develop subsequently Zeidler et al. Acta Derm Venereol. 2018 Treatment for PN . m- and kappa opioid receptor of Step antagonists sleep . Immunosuppressants the . Thalidomide injection 4 . NK-1 inhibitors treat treatment : . Topical KAL , Capsaicin Step 3 . Antidepressants intralesional , necessary if concomitant ); emollients , . Gabapentinoids lesions Step 2 psychsomatic single , disease (in .
    [Show full text]
  • The Neurokinin-1 Receptor Is Expressed with Gastrin-Releasing
    Research Articles: Cellular/Molecular The neurokinin-1 receptor is expressed with gastrin-releasing peptide receptor in spinal interneurons and modulates itch https://doi.org/10.1523/JNEUROSCI.1832-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.1832-20.2020 Received: 15 July 2020 Revised: 25 August 2020 Accepted: 21 September 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Title: The neurokinin-1 receptor is expressed with gastrin-releasing peptide receptor in spinal 2 interneurons and modulates itch 3 4 Abbreviated Title: Neurokinin-1 receptor spinal neurons mediate itch 5 6 7 Authors: Tayler D. Sheahan1, Charles A. Warwick1, Louis G. Fanien1, Sarah E. Ross1 8 9 10 1Pittsburgh Center for Pain Research and Department of Neurobiology, University of Pittsburgh, 11 Pennsylvania 12 13 Corresponding author: Sarah E. Ross, Department of Neurobiology, University of Pittsburgh, 14 200 Lothrop Street, Pittsburgh, PA, e-mail: [email protected] 15 The authors have no conflicts of interest to declare. 16 17 18 Number of text pages: 19 19 20 21 Number of figures and tables: 5 figures 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 1 50 Abstract 51 52 The neurokinin-1 receptor (NK1R, encoded by Tacr1) is expressed in spinal dorsal horn 53 neurons and has been suggested to mediate itch in rodents.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,493 B2 Weglicki Et Al
    US009687493B2 (12) United States Patent (10) Patent No.: US 9,687,493 B2 Weglicki et al. (45) Date of Patent: *Jun. 27, 2017 (54) USE OF NK-1 RECEPTOR ANTAGONISTS ionized Mg, Mg metabolism and electrolytes in serum of human FOR TREATING HYPOMAGNESEMLA, volunteers.” Journal of the American College of Nutrition, 1994; NEUROGENIC INFLAMMATION, AND 13(5): 447-454. CARDAC DYSFUNCTIONASSOCATED Barbagallo et al., “Magnesium homeostasis and aging.” Magnesium WITH EGFR-BLOCKING DRUGS Research, 2009; 22(4): 235-246. Cao et al., “Methionine Sulfoxide reductase B1 (MSrB1) recovers TRPM6 channel activity during oxidative stress.” Journal of Bio (71) Applicant: THE GEORGE WASHINGTON logical Chemistry, Aug. 20, 2010; 285(34):26081-7. UNIVERSITY, Washington, DC (US) Chen et al., “Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.” Circulation, 2008; (72) Inventors: William B. Weglicki, Potomac, MD 117: 84-95. (US); Iu Tong Mak, Gaithersburg, MD Dehlin et al., “Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hyper (US) tension.” International Journal of Cardiology, 2013 12; 168(5):4643-51. (73) Assignee: THE GEORGE WASHINGTON Dimke et al., “Effects of the EGFR Inhibitor Erlotinib on Magne UNIVERSITY, Washington, DC (US) sium Handling.” Journal of the American Society of Nephrology, Aug. 2010; 21 (8): 1309-16. doi:10.1681/ASN. 2009111153. Epub (*) Notice: Subject to any disclaimer, the term of this Jul. 1, 2010. patent is extended or adjusted under 35 Doherty et al., “Multi-parameter in vitro toxicity testing of crizotinib, Sunitinib, erlotinib, and nilotinib in human U.S.C.
    [Show full text]